Merck KGaA (FRA:MRK) received a €108.00 ($125.58) target price from equities research analysts at UBS Group in a research report issued to clients and investors on Monday, April 1st, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s target price would suggest a potential upside of 11.69% from the company’s current price.
MRK has been the subject of a number of other reports. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a “buy” rating in a report on Tuesday, February 12th. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, February 12th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, January 3rd. HSBC set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, March 11th. Finally, Barclays set a €78.00 ($90.70) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Tuesday, January 15th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of €101.00 ($117.44).
Shares of FRA:MRK opened at €96.70 ($112.44) on Monday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.